Mono Pharmacare Ltd vs Sanofi India Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 03, 2026

Key Highlights

The Latest Trading Price of Mono Pharmacare Ltd is ₹ 13.25 as of 29 Apr 15:30 . The p/e ratio of Mono Pharmacare Ltd changed from 32 to 13.2 over 2 quarters. This represents a CAGR of -82.98% The p/e ratio of Sanofi India Ltd changed from 30.8 to 0 over 5 quarters. This represents a CAGR of -100.00% The market cap of Mono Pharmacare Ltd changed from ₹ 77.92 crore to ₹ 40.81 crore over 2 quarters. This represents a CAGR of -72.57% The market cap of Sanofi India Ltd changed from ₹ 18578 crore to ₹ 0 crore over 5 quarters. This represents a CAGR of -100.00% The Revenue of Mono Pharmacare Ltd is ₹ 0 crore as of Jun '24 .The Revenue of Sanofi India Ltd is ₹ 578.9 crore as of Jun '24 . The EBITDA of Mono Pharmacare Ltd is ₹ 0 crore as of Jun '24 .The EBITDA of Sanofi India Ltd is ₹ 178.5 crore as of Jun '24 . The Net Profit of Mono Pharmacare Ltd is ₹ 0 crore as of Jun '24 .The Net Profit of Sanofi India Ltd is ₹ 136.6 crore as of Jun '24 . The dividend payout of Mono Pharmacare Ltd changed from 0 % to 0 % over 8 quarters. This represents a CAGR of 0.0% The dividend payout of Sanofi India Ltd changed from 119.34 % to 0 % over 8 quarters. This represents a CAGR of -100.00% .

About Mono Pharmacare Ltd

Mono Pharmacare Limited was originally formed as a Partnership Firm in the name and style of 'M/s.
Mono Chemist' through Partnership Deed dated May 06, 1994.
The Partnership Firm was then converted into Public Limited company in the name of Mono Pharmacare Limited vide Certificate of Incorporation dated October 17, 2022, was issued by the Registrar of Companies, Ahmedabad.
The Company is engaged in the business of marketing and distribution of pharmaceutical products. The product portfolio comprises of a wide range of drugs like Antibiotics, Antifungal, Anti CoughCold & Anti-allergic, Antacid and Antiemetics, Analgesics and Antipyretics, Nutraceuticals, Skincare, Antiseptic, Cardiac and Diabetic & Cosmetics etc. getting products manufactured through contract manufacturing. Supal Distributors LLP, a Partnership Firm, was incorporated on November 24, 2016, with the Promoters of Company, Panilam Lakhatariya and Supal Lakhatariya, being the Original Partners.

About Sanofi India Ltd

Sanofi India Limited, was initially incorporated as 'Aventis Pharma Limited' in May, 1956.
The Company changed its name from Aventis Pharma Limited to Sanofi India Limited on May 11, 2012.
The Company is amongst the leading multinational companies (MNCs) in the Indian Pharmaceutical Market.
The Company is primarily engaged in the business of manufacturing and trading of drugs s and pharmaceuticals.
It has its own manufacturing facility at Goa.

FAQs for the comparison of Mono Pharmacare Ltd and Sanofi India Ltd

Which company has a larger market capitalization, Mono Pharmacare Ltd or Sanofi India Ltd?

Market cap of Mono Pharmacare Ltd is 23 Cr while Market cap of Sanofi India Ltd is 8,111 Cr

What are the key factors driving the stock performance of Mono Pharmacare Ltd and Sanofi India Ltd?

The stock performance of Mono Pharmacare Ltd and Sanofi India Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Mono Pharmacare Ltd and Sanofi India Ltd?

As of May 3, 2026, the Mono Pharmacare Ltd stock price is INR ₹13.25. On the other hand, Sanofi India Ltd stock price is INR ₹3522.25.

How do dividend payouts of Mono Pharmacare Ltd and Sanofi India Ltd compare?

To compare the dividend payouts of Mono Pharmacare Ltd and Sanofi India Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.